Thereby, patients with a down-regulated low to moderate (+/++) α6 immunostaining at the invasion front shared a 6.41 times increased risk for tumor relapse (95% CI: 1.88–21.78), a 5.11 times increased risk for shortened tumor-associated survival (95% CI: 1.47–17.81), and a 3.04 times increased risk for shortened overall survival (95% CI: 1.13–8.21) compared to patients with a distinct strong (+++) α6 staining. This evidence concerns the gene TWF1 and neoplasm.